Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2025-12-25 @ 10:25 PM
Study NCT ID:
NCT05011058
Status:
TERMINATED
Last Update Posted:
2025-07-28
First Post:
2021-08-02
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Sponsor:
Viracta Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-28
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-01-31
Completion Date Type:
ACTUAL
First Submit Date:
2021-08-02
First Submit QC Date:
None
Study First Post Date:
2021-08-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-28
Results First Submit QC Date:
None
Results First Post Date:
2025-07-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-08
Last Update Post Date:
2025-07-28
Last Update Post Date Type:
ACTUAL